



Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment

Guest Editors:

Dr. Javier Garcia-Pardo

Institut de Biotecnologia i de
Biomedicina (IBB), Universitat
Autònoma de Barcelona, 08193
Bellaterra, Barcelona, Spain

Prof. Dr. Salvador Ventura

1. Institute of Biotechnology and
Biomedicine, Autonomous
University of Barcelona, 08193
Bellaterra, Spain
2. Department of Biochemistry
and Molecular Biology,
Autonomous University of
Barcelona, 08193 Bellaterra,
Spain

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editors

Neurodegenerative disorders are typically characterized by the progressive loss of specific populations of neurons in the brain. Despite recent advances in the field, most of the molecular mechanisms involved in disease progression are not completely understood. However, since protein aggregation is a central event in neurological disorders, a variety of novel approaches are focused on developing novel pharmacologically active molecules targeting this process. Without doubt, such ground-breaking discoveries will facilitate the structure-based design of novel functional and specific protein aggregation inhibitors. Additionally, we focus on nanomaterials targeting neurodegenerative disorders as efficient drug delivery systems.

The focus of this Special Issue is on the development and identification of novel molecules and therapeutic approaches dedicated to treat neurodegenerative diseases. The topics include but are not limited to: the design and development of novel protein-aggregation inhibitors; drug delivery using nanotechnology; and the development and characterization of pharmacologically active compounds targeting proteostasis and neurodegeneration





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma